About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The group of Clinical Neuroimmunology - Centre d'Esclerosi Múltiple de Catalunya (Cemcat) at the Vall d'Hebron Institut de Recerca (VHIR) is a multidisciplinary group dedicated to clinical assistance, physical and cognitive rehabilitation, and clinical and basic research on multiple sclerosis (MS). Cemcat is a national but also an international reference center in the clinical assistance of MS patients. The research performed in the group is divided and further combined in clinical and basic research. In addition, basic research has a marked translational character since the ultimate goal of the group is to improve the quality of life of patients suffering from MS, through in-depth knowledge of the pathogenic mechanisms of the disease and the development of new and more effective therapeutic approaches.
IP: Manuel Comabella Lopez Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 248720 Reference: BEHIND-MS_HE-HLTH2023 Duration: 01/12/2023 - 30/11/2028
IP: Manuel Comabella Lopez Collaborators: Laia Perez Lasarte, Elisa Marín Ordovás, Miriam Izquierdo Sans Funding agency: Fundació Institut de Recerca HUVH Funding: 69188.74 Reference: VPHD/ELISA_M Duration: 01/04/2023 - 31/03/2026
IP: x Collaborators: x, Miriam Izquierdo Sans Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 236350 Reference: RYC2021-033528-I Duration: 01/01/2023 - 31/12/2027
IP: Convocatoria Juan Rodés (Preliminar: Enfermedades neurológicas mediadas por anticuerpos antineuronales) Collaborators: Genoveva Arqueros Sánchez, Convocatoria Juan Rodés (Preliminar: Enfermedades neurológicas mediadas por anticuerpos antineuronales), Helena Ariño Rodríguez, Miriam Izquierdo Sans Funding agency: Instituto de Salud Carlos III Funding: 180000 Reference: JR22/00071 Duration: 20/02/2023 - 19/02/2026
A study conducted at the Catalan Multiple Sclerosis Centre (Cemcat) shows that the lack of a reduction in neurofilament light chain during the first year of treatment is associated with a higher risk of subsequent disease activity.
The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.
An international study led by researchers from Vall d’Hebron shows that simple tests that patients can perform themselves help detect changes in disability that may occur even in the absence of disease relapses.
Simoa HD1 equipment
2026 SIMOA HD1 Rates
PDF 0.47 MB
SIMOA HD1 Rates - historical
PDF 0.15 MB
